• Bufalin: Mechanism, STK33, and Cancer Research

  2026-09-16

  Bufalin is a cardiotonic steroid with reported apoptosis-inducing, differentiation-inducing, and protein-degradation activities in cancer research. Recent evidence identifies STK33 as a Bufalin-binding target in triple-negative breast cancer models, while product specifications define its chemical identity and handling requirements.

• Merbromin Inhibition of SARS-CoV-2 3CLpro

  2026-09-16

  The reference study identifies merbromin as a selective, mixed-type inhibitor of the SARS-CoV-2 main protease 3CLpro through enzyme screening, kinetic analysis, binding assays, and molecular docking. Its comparison with Proteinase K, trypsin, and papain shows how orthogonal protease controls can distinguish target inhibition from nonspecific protein hydrolysis.

• FK866 (APO866) Workflows for NAD Cancer Research

  2026-09-15

  FK866 (APO866) enables controlled NAMPT inhibition for NAD-depletion studies, AML models, and biomarker-led combination experiments. This guide connects practical assay design with emerging evidence that RAS/PI3K pathway status can influence responses to FK866 plus PARP inhibition.

• Moesin and Endothelial Injury in Sepsis

  2026-09-15

  The reference study identifies circulating moesin as a candidate biomarker associated with sepsis severity and endothelial barrier disruption. By combining patient measurements, murine LPS and cecal ligation and puncture models, and HMEC experiments, it links moesin to Rock1/MLC and NF-κB signaling while showing that moesin silencing reduces inflammatory and permeability responses.

• SNS-032: A CDK9-Centered Assay Strategy

  2026-09-14

  SNS-032 (BMS-387032) is a selective CDK2, CDK7, and CDK9 inhibitor whose strongest biochemical activity is against CDK9. This article develops an assay-centered framework linking RNA polymerase II phosphorylation, cancer pharmacology, and carefully bounded interpretation of emerging SARS-CoV-2 host-factor research.

• SGI-1027 Induces Apoptosis in Huh7 Cells

  2026-09-14

  The 2018 reference study examined how the non-nucleoside DNA methyltransferase inhibitor SGI-1027 affects Huh7 hepatocellular carcinoma cells. Its main contribution was linking reduced viability to apoptosis-associated changes in Bcl-2 and Bax, while finding no significant cell-cycle redistribution after treatment.

• Phosphorylated NPY1R in Intracranial Aneurysm

  2026-09-13

  The reference study identifies phosphorylated NPY1R as a mechanistic link between vascular smooth muscle cell phenotypic transition, inflammatory signaling, macrophage polarization, and intracranial aneurysm progression. By combining patient tissue analysis, a hypertensive elastase-induced mouse model, molecular assays, pharmacological intervention, and macrophage depletion, the work provides a framework for testing NPY1R-centered mechanisms in aneurysm biology.

• Wnt agonist 1: Wnt/GPX4 Assay Workflows

  2026-09-12

  Wnt agonist 1 (BML-284) provides a controllable way to activate canonical Wnt signaling in reporter, differentiation, and cancer-resistance models. This guide translates the Wnt/NR2F2/GPX4 findings from lung cancer brain metastasis research into practical assay designs, dose planning, and troubleshooting steps.

• Cimetidine in BBB Transport and Cancer Assays

  2026-09-11

  Cimetidine supports two complementary research workflows: H2 receptor biology in gastrointestinal cancer models and controlled permeability testing in surrogate blood-brain barrier systems. This guide translates the latest LLC-PK1-MDR1 findings into practical assay design, stock preparation, transport calculations, and troubleshooting decisions.

• Z-YVAD-FMK: Caspase-1 Inhibitor Workflow

  2026-09-11

  Z-YVAD-FMK is a cell-permeable, irreversible caspase-1 inhibitor for separating inflammasome-driven pyroptosis from apoptosis and other forms of cell death. This workflow combines practical dosing, orthogonal readouts, and species-aware interpretation for cancer research, inflammatory models, and gasdermin studies.

• PA-824: From Nitro-Reduction to TB Regimens

  2026-09-10

  A mechanistic and translational guide to using PA-824 as a tuberculosis research compound, with practical assay parameters and a regimen-design perspective informed by terminal oxidase biology.

• EdU Cell Proliferation Kit: From Signal to Mechanism

  2026-09-10

  The EdU Cell Proliferation Kit (TMB) converts DNA synthesis into a quantitative colorimetric readout for mechanistic cell proliferation studies. This guide explains how to use the assay to connect ARL4C-associated synoviocyte biology with S-phase measurement, pharmacodynamic drug evaluation, and genotoxicity testing.

• Recombinant Annexin V for Apoptosis Detection

  2026-09-09

  Brumatti, Sheridan, and Martin describe an integrated workflow for bacterial expression, nickel-affinity purification, FITC labeling, and application of recombinant annexin V. The method provides a practical way to detect phosphatidylserine exposure by flow cytometry or fluorescence microscopy while clarifying why this signal should be interpreted alongside membrane-integrity measurements.

• Bicinchoninic Acid Assay (BCA) Kit Guide

  2026-09-09

  The Bicinchoninic Acid Assay (BCA) Protein Quantification Kit, SKU K4102, supports low-concentration total protein measurement in dilute biochemical samples, cell lysates, and many detergent-containing preparations. It is intended for scientific research and sample-normalization workflows, not diagnostic, clinical, or medical testing.

• DiscoveryProbe Protease Inhibitor Library Workflow

  2026-09-08

  Build a mechanism-first protease inhibition workflow that moves from automated screening to orthogonal validation. The DiscoveryProbe™ Protease Inhibitor Library combines broad chemical coverage with pre-dissolved compounds for biochemical, cellular, and high-content assay development.

7924 records 1/529 page Next 12345 下5页 Last page